التكنولوجيا وأخبارها بوابة الإمارات لتكنولوجيا المعلومات والإتصالات
Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights
Company, Taps Industry Experts Joseph A. Boystak as
Chairman of the Board and Ameet Nathwani, MD, as
Chairman of its Newly Formed Medical Strategy Advisory Board
DRE recruits additional expertise for strategic guidance and
advice to accelerate adoption of DOC Label™ , DOC Search™
and DOC Analytics™
DRE is pleased to welcome Joe Boystak as Chairman of the
Board and Ameet Nathwani, MD, as Chairman of its newly
formed Medical Strategy Advisory Board (MSAB). These
enhancements to the Company reflect the expanded need
for keen guidance in this unprecedented time of
convergence between expert AI-enabled technology in
healthcare and the exponential growth of clinical
information. DRE is dedicated to applying sophisticated
data science with advanced AI to generate quicker, deeper,
more nuanced regulatory-grade scientific and clinical
insights for the betterment of patient outcomes.
Boystak is an experienced healthcare venture capitalist and
senior healthcare investment banker having been Founding
Managing Partner at Health2047 Capital Partners and
Founding Managing Director, Global Life Sciences at
Jefferies. He is CEO of Brightwaters Capital and is a serial
co-founder/investor in biomedical, med tech, health
information technology, and artificial intelligence
companies with spinouts from UCLA, Johns Hopkins,
Harvard/Massachusetts General Hospital, Memorial Sloan
Kettering Cancer Center, among others. Boystak is also
named co-inventor on 5 issued US/EU patents for first-in-
class medical technology developed by Bruin Biometrics
LLC, a company he co-founded and was its initial Chairman.
He has served on more than a dozen corporate and non-
profit boards and currently serves on the Johns Hopkins
Bloomberg School of Public Health and Southern California
Biomedical Council (SoCalBio) Boards.
“I am honored to join the DRE Board as its Chairman. DRE’s
industry leading SaaS platform is facilitating AI-driven drug
discovery as pharma and life sciences companies rapidly
adopt this technology,” stated Boystak. “Our SaaS platform
enables, among others, researchers and drug developers to
optimize drug design, improve clinical trial effectiveness,
rapidly explore repurposing of compounds, refine FDA label
strategies and improve product life cycle management –
thus creating substantial ROI for our clients.”
Ameet Nathwani, MD, is Chairman of the newly created
MSAB, which will initially consist of five members that
represent industry, specialty medical societies, regulatory,
data science and patient advocacy. Dr. Nathwani’s most
recent position as Executive Vice President, Chief Medical
Officer and Chief Digital Officer at Sanofi provides a great
framework for the MSAB to inform DRE on strategy,
regulatory requirements, research and development,
technology and trends in clinical care. The MSAB will also
advise on healthcare ecosystem partners for DRE to
collaborate with to accelerate treatments and cures.
“It is a privilege to be appointed as the Chairman of the
DRE MSAB. At a time when the volume and complexity of
scientific data is increasing exponentially, the AI-driven
DRE platform provides a state-of-the-art tool which gives
healthcare organizations the ability to deconvolute critical
scientific data. This agile approach to make rigorous and
rapid decisions of real-world data is critical to innovate in
this dynamic century of biology,” said Ameet Nathwani, MD.
“The MSAB will advise DRE on enhancing the many
scientific and healthcare applications of the platform in
order to best support a diverse spectrum of partners that
will ultimately benefit physicians and patients.”
“With our expanded SaaS platform now including the
launch of DOC Analytics™ we are that much closer to
achieving our mission of democratizing sophisticated
analysis of clinical studies and real-world data for
researchers,” added Bob Battista, MBA, FRCPH, FRCP Edin.
“We have been fortunate to be backed by a committed
group of investors and Board members that Joe will now
lead as we chart our next stage of growth. We are similarly
privileged to have Dr. Nathwani lead our newly established
MSAB. Ameet’s deep sector knowledge and passion for
DRE’s SaaS platform provide an incredible basis for guiding
our healthcare strategy.”
Joe Boystak and Ameet Nathwani, MD, join a distinguished
group of Corporate Board members at DRE that include:
Marc Rapaport, immediate past Chairman of DRE,
immediate past Chairman of the Board of Cedars-Sinai
Medical Center (Los Angeles), private equity investor, and
former Executive Vice President and Co-Head of Capital
Markets at Drexel Burnham Lambert and Jefferies; Vivek
Garipalli, CEO and Co-Founder Clover Health, Co-Founder
CarePoint Health, and an active investor in early stage
healthcare companies, including founding investor in
Flatiron; Ted Meisel, serial healthcare and technology
entrepreneur, Executive Founder of AVIA, Executive
Chairman of WiserCare, Senior Advisor NextEquity
Partners, past Senior Advisor to the Center for Medicare
and Medicaid Services (CMS), past President Yahoo Search
and past CEO of Overture (acquired by Yahoo); Ananth
Bhogaraju, Founder and Managing Director Seven Hills
Healthcare Advisors and past Vice Chairman Americas
Healthcare Investment Banking Deutsche Bank; Larry
Burstein, a healthcare focused Family Office career fund
manager; Bob Battista, Co-Founder and CEO DRE, serial
healthcare and technology entrepreneur, past Executive
Vice President at TheraCom, the first ever specialty
pharmacy; and Todd Feinman, MD, Co-Founder and Chief
Medical Officer DRE, Hospitalist at Cedars-Sinai Medical
Center (Los Angeles) and Director of a large Independent
Physician Association.
